ArticleFrontiers in pharmacology2026
Yttrium-90 radioembolization as an in vivo immune modulator: clinical evidence and pharmacologic implications.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yttrium-90 (Y-90) transarterial radioembolization (TARE) is widely used for the treatment of primary and metastatic liver tumors and has traditionally been viewed as a purely locoregional radiotherapeutic modality. However, accumulating clinical evidence supports the concept that Y-90 TARE can induce measurable immunologic changes in patients, detectable both systemically and within the tumor microenvironment. Longitudinal analyses of peripheral blood and tumor tissue from patients with hepatocellular carcinoma and liver metastases demonstrate transient immune activation, myeloid remodeling, and adaptive immune perturbations following treatment. Notably, these immune-stimulatory signals may coexist with counter-regulatory mechanisms, including upregulation of immune checkpoint pathways, suggesting a dynamic balance between immune priming and adaptive resistance. In this Perspective, we synthesize available
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.